Table 3.

Step 1. Survival in association with patients’ SEP adjusted for treatment, patients’ and disease characteristics

Main components		Model 1.0 (M1.0)			Model 1.1			Model 1.2			Model 1.3			Model 1.4			Model 1.5			Model 1.6		M 1.7
					M1.0 + perf. Status			M1.0 + AML ont			M1.0 + WBC.			M1.0 + cyto. Progn.			M1.0 + treatment			All but treatment		Fully adjusted
		HR	[95% CI]		HR	[95% CI]		HR	[95% CI]		HR	[95% CI]		HR	[95% CI]		HR	[95% CI]		HR	[95% CI]	HR	[95% CI]
Age		1.04	[1.03; 1.05]		1.03	[1.02; 1.05]		1.04	[1.03; 1.05]		1.04	[1.03; 1.05]		1.04	[1.02; 1.05]		1.01	[1.00; 1.03]		1.03	[1.02; 1.05]	1.02	[1.00; 1.03]
Sex	Men	ref			ref			ref			ref						ref			Ref		ref
	Women	0.88	[0.73; 1.07]		0.86	[0.71; 1.04]		0.87	[0.72; 1.05]		0.89	[0.74; 1.08]		0.84	[0.69; 1.01]		0.87	[0.72; 1.05]		0.81	[0.67; 0.98]	0.82	[0.68; 1.00]
Patients’ SEP (quintile of deprivation score)	Q1 – least	ref			Ref			Ref			Ref						Ref			ref		Ref
	Q2	1.14	[0.85; 1.53]		1.11	[0.83; 1.50]		1.08	[0.80; 1.45]		1.17	[0.87; 1.35]		1.06	[0.79; 1.42]		1	[0.84; 1.50]		1.01	[0.75; 1.37]	0.96	[0.71; 1.29]
	Q3	0.89	[0.67; 1.18]		0.85	[0.64; 1.13]		0.83	[0.62; 1.11]		0.88	[0.66; 1.17]		0.89	[0.67; 1.18]		0.84	[0.69; 1.22]		0.80	[0.60; 1.07]	0.78	[0.58; 1.04]
	Q4	1.07	[0.82;	1.40]	1.02	[0.78; 1.33]		1.03	[0.79; 1.35]		1.07	[0.82; 1.40]		1.06	[0.81; 1.38]		1	[0.82; 1.40]		0.99	[0.75; 1.30]	0.94	[0.71; 1.24]
	Q5 – most	1.39	[1.04; 1.87]		1.37	[1.02; 1.84]		1.31	[0.97; 1.76]		1.47	[1.10; 1.97]		1.30	[0.97; 1.75]		1.35	[1.12; 2.01]		1.28	[0.95; 1.73]	1.29	[0.95; 1.74]
Charlson comorbidity index	0	ref			ref			ref			ref						ref			ref		ref
	1	1.1	[0.86; 1.41]		1.02	[0.80; 1.31]		1.08	[0.85; 1.38]		1.15	[0.90; 1.47]		1.09	[0.86; 1.40]		1.01	[0.79; 1.29]		1.07	[0.83; 1.37]	1.00	[0.78; 1.28]
	2+	1.29	[1.01; 1.66]		1.18	[0.92; 1.52]		1.21	[0.94; 1.56]		1.3	[1.01; 1.66]		1.35	[1.06; 1.73]		1.13	[0.88; 1.45]		1.19	[0.92; 1.54]	1.08	[0.83; 1.41]
	Undefined	2.1	[1.60; 2.76]		1.89	[1.39; 2.56]		1.88	[1.40; 2.53]		2.06	[1.56; 2.73]		1.97	[1.49; 2.61]		1.29	[0.96; 1.74]		1.66	[1.20; 2.31]	1.25	[0.89; 1.75]
Performance status	0/1				ref															Ref		ref
	2				1.51	[1.16; 1.97]														1.49	[1.15; 1.95]	1.50	[1.15; 1.95]
	3/4				2.36	[1.70; 3.28]														1.90	[1.34; 2.68]	1.72	[1.22; 2.42]
	Undefined				1.75	[1.24; 2.48]														1.52	[1.04; 2.20]	1.29	[0.88; 1.88]
AML ontogeny	AML de novo							ref												Ref		ref
	Secondary AML (post treatment / MDS)							1.25	[1.03; 1.52]											1.21	[0.99; 1.48]	1.12	[0.91; 1.38]
	Undefined							1.56	[0.90; 2.72]											1.60	[0.90; 2.83]	1.52	[0.86; 2.70]
White blood cell (WBC) counts (tercile)	Tercile 1 – low										ref											Ref
	Terticle 2 – intermediate										1.42	[1.10; 1.83]								1.38	[1.06; 1.79]	1.34	[1.04; 1.74]
	Terticle 3 – high										2.24	[1.66; 3.01]								2.16	[1.59; 2.93]	2.36	[1.74; 3.20]
	Undefined										2.9	[1.50; 5.60]								2.28	[1.14; 4.56]	2.10	[1.05; 4.21]
Cytogenetic prognosis	Favorable/Intermediate
	Unfavorable													2.00	[1.64; 2.43]					2.01	[1.64; 2.46]	1.72	[1.38; 2.13]
	Undefinable													1.99	[1.34; 2.96]					1.88	[1.24; 2.86]	1.44	[0.95; 2.18]
Treatment	Intensive chemotherapy																ref
	Low intensive therapy																1.53	[1.19; 1.96]				1.36	[1.01; 1.82]
	Best supportive care																4.11	[2.93; 5.77]				3.24	[2.21; 4.76]
Time varying component
Time * Performance status					0.9998 [0.9997;0.9999]															0.9999 [0.9998; 1.0000]		0.9999 [0.9998; 1.0000]
Time * White blood cell counts											0.9993 [0.9990; 0.9996]									0.9993 [0.9989; 0.9996]		0.9992 [0.9990; 0.9996]

Adjusted hazard ratios [95% Confidence Intervals] of overall mortality from Adjusted Cox proportional hazards model with time dependent variables (n = 592)